These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 22399285

  • 1. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
    Le VN, Hoang Thi TH, Robins E, Flament MP.
    AAPS PharmSciTech; 2012 Jun; 13(2):477-84. PubMed ID: 22399285
    [Abstract] [Full Text] [Related]

  • 2. In vitro evaluation of powders for inhalation: the effect of drug concentration on particle detachment.
    Le VN, Hoang Thi TH, Robins E, Flament MP.
    Int J Pharm; 2012 Mar 15; 424(1-2):44-9. PubMed ID: 22207163
    [Abstract] [Full Text] [Related]

  • 3. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN, Bierend H, Robins E, Steckel H, Flament MP.
    Int J Pharm; 2012 Jan 17; 422(1-2):75-82. PubMed ID: 22036653
    [Abstract] [Full Text] [Related]

  • 4. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug 17; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 5. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM, MacRitchie HB, Marriott C, Martin GP.
    Int J Pharm; 2007 Mar 21; 333(1-2):45-55. PubMed ID: 17064863
    [Abstract] [Full Text] [Related]

  • 6. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr 21; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 7. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X, Li J, Wen X, Ma S, An Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2024 Oct 25; 664():124609. PubMed ID: 39163928
    [Abstract] [Full Text] [Related]

  • 8. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D, Martin GP, Marriott C.
    J Pharm Sci; 2009 Feb 25; 98(2):503-15. PubMed ID: 18506819
    [Abstract] [Full Text] [Related]

  • 9. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2010 Nov 25; 76(3):464-9. PubMed ID: 20854906
    [Abstract] [Full Text] [Related]

  • 10. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW, Schneider M, Morrical BD, Imanidis G.
    J Pharm Sci; 2018 Apr 25; 107(4):984-998. PubMed ID: 29247741
    [Abstract] [Full Text] [Related]

  • 11. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate.
    Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ.
    J Pharm Sci; 2010 Aug 25; 99(8):3415-29. PubMed ID: 20222025
    [Abstract] [Full Text] [Related]

  • 12. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW.
    Int J Pharm; 2006 Mar 09; 310(1-2):81-9. PubMed ID: 16442246
    [Abstract] [Full Text] [Related]

  • 13. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y, Qin L, Li J, Su J, Song R, Zhang X, Guan J, Mao S.
    AAPS J; 2021 Apr 15; 23(3):55. PubMed ID: 33856568
    [Abstract] [Full Text] [Related]

  • 14. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
    Flament MP, Leterme P, Gayot A.
    Int J Pharm; 2004 May 04; 275(1-2):201-9. PubMed ID: 15081150
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P, Du J, Smyth HDC.
    J Pharm Sci; 2017 Jan 04; 106(1):366-376. PubMed ID: 27939234
    [Abstract] [Full Text] [Related]

  • 16. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
    Ooi J, Gill C, Young PM, Traini D.
    Curr Drug Deliv; 2015 Jan 04; 12(1):40-6. PubMed ID: 25146438
    [Abstract] [Full Text] [Related]

  • 17. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO, Molokhia AM, Elsayed MM.
    Eur J Pharm Biopharm; 2015 Oct 04; 96():291-303. PubMed ID: 26275831
    [Abstract] [Full Text] [Related]

  • 18. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
    Müller T, Krehl R, Schiewe J, Weiler C, Steckel H.
    Eur J Pharm Biopharm; 2015 May 04; 92():130-8. PubMed ID: 25769680
    [Abstract] [Full Text] [Related]

  • 19. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
    Faulhammer E, Wahl V, Zellnitz S, Khinast JG, Paudel A.
    Int J Pharm; 2015 Aug 01; 491(1-2):231-42. PubMed ID: 26136200
    [Abstract] [Full Text] [Related]

  • 20. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS, Lau R.
    Int J Pharm; 2010 Feb 15; 386(1-2):6-14. PubMed ID: 19922775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.